Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

CytoMed has generated the critical cell banks for the iPSC-derived hybrid of gamma delta T and Natural Killer cell technology and is currently undergoing process development into a potentially very ...

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company") today released a letter to shareholders from the Chairman of the Company's Board ...

Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So, the natural question for Verve Therapeutics (NASDAQ:VERV) ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Dyne Therapeutics is a clinical stage biotech concern with just over $700 million of cash on its balance sheet. Learn more about DYN stock here.

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has been given a consensus rating of “Moderate Buy” by the ...

Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3B. The listing ...

Peptide Therapeutics MarketThe global peptide therapeutics market is set for remarkable expansion, with its valuation projected to grow from USD 42.1 billion in 2024 to USD 117.4 billion by 2034. The ...

So, the natural question for Monte Rosa Therapeutics (NASDAQ:GLUE) shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash burn as ...